BIO — BIO-RAD LABORATORIES, INC.
—
NYSE ·
Unknown ·
Unknown ·
CIK 12208 ·
Last close
$296.90
Market Cap
$6.44B
52W High
$312.85
52W Low
$236.73
ADV30
403,736
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 592,100,000 | 309,400,000 | 34,100,000 | -527,100,000 | 9,790,000,000 | 507,200,000 | 2,938,700,000 |
| Dec 2025 | 693,200,000 | 345,200,000 | 53,900,000 | 720,000,000 | 10,576,500,000 | 529,800,000 | 3,122,900,000 |
| Sep 2025 | 653,000,000 | 343,400,000 | 63,900,000 | -341,900,000 | 9,696,400,000 | 395,800,000 | 2,959,600,000 |
| Jun 2025 | 651,600,000 | 345,300,000 | 77,100,000 | 317,800,000 | 10,214,100,000 | 369,300,000 | 3,085,400,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$510,400,000
Investing CF
$-285,800,000
Financing CF
$-229,500,000
CapEx
$-153,200,000
Dividends Paid
—
Buybacks
$-241,400,000
EPS Diluted TTM
$6.07
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$7,649,200,000
Inventory
$770,500,000
Receivables
$426,200,000
ST Investments
$1,057,500,000
EBIT TTM
$271,600,000
Pretax Income TTM
$222,300,000
Interest Exp TTM
$49,300,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,589,900,032
EBITDA
$444,800,000
Free Cash Flow
$229,762,496
Enterprise Value
$7,513,882,112
Total Cash
$1,564,700,032
Total Debt
$1,378,200,064
Shares Out
21,700,560
Trailing EPS
$6.01
Book Value
$255.37
ROE
2.5%
ROA
1.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,583,200,000 | 218,600,000 | 759,900,000 | 10,576,500,000 | 3,122,900,000 | — | 532,200,000 |
| Dec 2024 | 2,566,500,000 | 269,000,000 | -1,844,200,000 | 9,364,100,000 | 2,794,800,000 | — | 455,200,000 |
| Dec 2023 | 2,671,200,000 | 337,800,000 | -637,300,000 | 12,299,100,000 | 3,557,900,000 | — | 374,900,000 |
| Dec 2022 | 2,802,200,000 | 475,100,000 | -3,627,500,000 | 13,501,666,000 | 3,886,414,000 | — | 194,400,000 |
TTM Snapshot
Revenues TTM
$2,709,673,000
NetIncome TTM
$4,524,682,000
OpCashFlow TTM
$0
Assets (Latest)
$9,364,100,000
Forward EPS
$9.72
News headlines (Yahoo Finance, 1h cache)
Is Elliott’s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)?
2026-05-25 11:11 · Yahoo
Elliott Targets Bio-Rad After 70% Stock Collapse
2026-05-22 17:25 · Yahoo
Stocks Settle Mixed as Iran War Remains Unresolved
2026-05-18 20:35 · Yahoo
Stocks Pressured by a Rebound in Crude Prices and Bond Yields
2026-05-18 15:25 · Yahoo
Stocks Mixed as Crude Oil Prices and Bond Yields Fall
2026-05-18 14:05 · Yahoo
Sector Update: Healthcare Stocks Decline Pre-Bell Monday
2026-05-18 13:18 · Yahoo
Bio-Rad to Participate in Upcoming Investor Conferences
2026-05-08 13:00 · Yahoo
Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out
2026-05-05 16:14 · Yahoo
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation,
2026-05-04 19:30 · Yahoo
How The Biocon (NSEI:BIOCON) Story Is Shifting As Analysts Recut Growth And Risk Assumptions
2026-05-04 18:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.